AntibioticDB

BOS-228, LYS228, ancremonam

Beta-lactam (monobactam)

Boston Pharmaceuticals (Licensed from Novartis AG)

Highest development stage: Phase 2
Development status: Active
Gram-negative activity
Mechanism of Action/Target pathogen: Bacterial infections
GtoPDB link: https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13161
Source: https://www.novartis.com/news/media-releases/novartis-licenses-three-novel-anti-infective-programs-boston-pharmaceuticals
Citation (1): https://aac.asm.org/content/62/10/e01200-18
Citation (2): https://aac.asm.org/content/63/7/e02592-18